Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial

被引：17

作者：

Haas, Naomi B.

Manola, Judith

Uzzo, Robert G.

Atkins, Michael B.

Wilding, George

Pins, Michael

Jewett, Michael A. S.

Kane, Christopher J.

Cella, David

Wagner, Lynne I.

Coomes, Bob

Wood, Christopher G.

Dutcher, Janice P.

Flaherty, Keith

DiPaola, Robert S.

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[4] Lombardi Comprehens Canc Ctr, Washington, DC USA

[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[6] Univ Illinois, Coll Med, Chicago, IL USA

[7] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

[8] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[9] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Our Lady Mercy Canc Ctr, Bronx, NY USA

[12] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA

[13] Rutgers Biomed & Hlth Sci, New Brunswick, NJ USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.7_suppl.403

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

403

引用

页数：1